Navigation Links
Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement
Date:2/1/2010

Astrogenetix is issuing the following statement applauding NASA's commitment to extend the life of the International Space Station (ISS) to 2020 or beyond.

(Vocus) February 1, 2010 -- Astrogenetix is issuing the following statement applauding NASA's commitment to extend the life of the International Space Station (ISS) to 2020 or beyond.

Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:

“We are excited to see such a significant commitment from the Obama Administration and NASA to extend the International Space Station to 2020 or beyond. The ISS National Lab provides us with one of our country’s most unique environments for conducting scientific research. Astrogentix is very proud of our results in discovering the salmonella vaccine during the National Lab Pathfinder missions. The vision outlined today will allow for continued discoveries of important vaccines like MRSA and provide a platform for many more discoveries in the future.”

About Astrogenetix, Incorporated
A subsidiary of Astrotech Corporation (Nasdaq: ASTC), Astrogenetix is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity. The Company offers a turn-key platform for pre-flight sample preparation, flight hardware, mission planning and operations, crew training and certification processes needed within the highly regulated and complex environment of manned space flight.

The statements in this document may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the company's Securities & Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3551324.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:7/20/2017)... -- Delta (NYSE: DAL ) customers now can use fingerprints ... Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National ... Delta,s biometric boarding pass experience that launched ... into the boarding process to allow eligible Delta SkyMiles Members who are ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):